Peter Voorhees, MD, Atrium Health

Articles

Dr. Voorhees on the Utilization of Proteasome Inhibitors for Newly Diagnosed Multiple Myeloma

November 2nd 2022

Peter Voorhees, MD, discusses developments in the efficacy and application of proteasome inhibitors for patients with newly diagnosed multiple myeloma.

Rapid Readouts: The Phase 1/2 ANCHOR Trial for Melphalan Flufenamide in Relapsed/Refractory Multiple Myeloma

January 18th 2021

Dr. Voorhees on Updated Results of the GRIFFIN Trial in Multiple Myeloma

December 7th 2020

Peter Voorhees, MD, a multiple myeloma specialist at Levine Cancer Institute, of Atrium Health, discusses updated results of the GRIFFIN trial in multiple myeloma.

Future of BCMA-Targeted Therapies in Multiple Myeloma

July 17th 2020

Bispecific Antibodies for Multiple Myeloma

July 17th 2020

Differentiating among CAR T Products for Multiple Myeloma

July 17th 2020

Development of CAR T Cells in Multiple Myeloma

July 17th 2020

Using Antibody-Drug Conjugates in Multiple Myeloma

July 17th 2020

BCMA-Targeted Therapies in Multiple Myeloma

July 17th 2020

BELLINI Trial; Venetoclax-Vd in Multiple Myeloma

July 17th 2020

BOSTON Study; SVd in Relapsed/Refractory Multiple Myeloma

July 17th 2020

Lenalidomide-Refractory Multiple Myeloma

July 17th 2020

Daratumumab With Carfilzomib in Frontline Multiple Myeloma

July 17th 2020

Management of Relapsed/Refractory Multiple Myeloma

July 17th 2020

Maintenance Therapy Approaches in Multiple Myeloma

July 17th 2020

MRD Monitoring in Multiple Myeloma

July 17th 2020

The Role of Transplant in Multiple Myeloma

July 17th 2020

Treating Transplant-Eligible and -Ineligible MM

July 17th 2020

Transplant-Ineligible Multiple Myeloma

July 17th 2020

Tolerability of Triplet Therapy in Multiple Myeloma

July 17th 2020